Ireland raised €1 billion in two well-received bond sales today as sentiment towards the economy, the National Treasury Management Agency (NTMA) said today
“I think people are more and more certain that Ireland is dealing with the… problems that we have and the bonds have rallied significantly,” NTMA deputy director Anthony Linehan said today. “Like all things that perform well people want to get on board.”
eBay today made it easy for sellers to find and subscribe to third-party applications that improve the efficiency and effectiveness of their eBay businesses. Available immediately through My eBay (my.ebay.com) for subscribers of Selling Manager and Selling Manager Pro are about a dozen applications that have been pre-approved by eBay to be embedded on eBay.com. eBay anticipates steady growth in the number of tools available through the Selling Manager Applications platform to address specific needs of eBay sellers including: shipping, inventory management, sales tracking and customer support.
Announcement Highlights/Key Facts:
All Selling Manager applications are free to try. An app store for eBay sellers, third-party applications are subscribed to at My eBay (my.ebay.com) with eBay managing billing on behalf of third-party developers.
In April, eBay announced that it would no longer charge sellers to subscribe to Selling Manager, turning it into an open platform where third-party developers could embed their applications into my.ebay.com, allowing them to connect with sellers directly.
More than 96,000 third-party developers have already built more than 13,000 live applications that consume eBay’s Web services. These developers – along with new applicants – form the base of a vibrant developer community and expanding application marketplace.
Today’s announcement is also the latest milestone in eBay’s commitment to making it easier for sellers of any size to start, grow and maintain their business on eBay. In July, eBay rolled out enhancements for search relevancy, the automation and speed of the resolution process for unpaid items, new bulk editing tools, and an update to its highly regarded Seller Dashboard. These changes were part of the launch of the company’s Top-rated seller status, which is awarded to sellers that are ranked highly by their buyers through eBay’s detailed seller-ratings feedback system.
Sellers can access the applications directory for Selling Manager and Selling Manager Pro by simply pointing their Web browsers to http://applications.ebay.com/. eBay’s Selling Manager and Selling Manager Pro currently have 270,000 active subscribers in the U.S. and the tools can be accessed at http://pages.ebay.com/selling_manager and http://pages.ebay.com/selling_manager_pro.
First Group of Applications Rolled Out
Over the course of this week, the first dozen embedded Selling Manager Applications will be rolled out. Users can easily find, subscribe and manage the applications they want and need with a single eBay sign-on. Some top solutions eBay users can try out for free in Selling Manager include:
Terapeak: Research before you sell. Research before you buy. Find the value of your items, discover new products to sell, and develop your selling strategy using Terapeak Marketplace Research.
HostedSupport: HostedSupport’s customer support tool helps you answer the questions customers ask about your listings. ezSupport for eBay is integrated directly with the “Ask a question” link on your listings, providing direct access to your searchable FAQ knowledge-base and/or intelligent auto-response messaging.
ahTEXT: Keeps you connected to your eBay account by sending you a text message the moment that a buyer asks a question, makes an offer, buys an item, leaves Feedback or files a dispute.
For more background on any of these developers, please visit the eBay API Success Stories page.
Quotes
Dinesh Lathi, VP of eBay Seller Experience
“eBay’s Selling Manager Applications Platform is an app store for eBay sellers that makes it easy to find and subscribe to tools that can help our customers increase the efficiency and velocity of their businesses on eBay.”
Kumar Kandaswamy, Senior Manager, eBay Platform
“eBay’s API platform already attracts 96,000 developers who have built more than 13,000 live applications. Selling Manager Applications addresses the need of developers to more readily connect eBay sellers who are seeking useful tools for their eBay businesses. Under the eBay Selling Manager Applications revenue sharing agreement, applications that pass eBay’s rigorous approval process will be put in front of an active audience of more than 270,000 professional eBay sellers. By managing the billing on behalf of developers, we are simplifying the process for both eBay sellers and third-party developers.”
Andrew E.R. Sukow, Co-Founder, CTO, Terapeak
“The ability to embed our application inside My eBay gives us an opportunity to both reach sellers in an entirely new, more personalized way and also capture revenue streams. We’ll also get a much better sense of the needs of sellers as we think about creating new applications.”
Video Overview
A video overview of the eBay Selling Manager Applications platform: http://www.businesswire.com/multimedia/home/20090401005446/en/1778299
About eBay
Founded in 1995, eBay Inc. connects hundreds of millions of people around the world every day, empowering them to explore new opportunities and innovate together. eBay Inc. does this by providing the Internet platforms of choice for global commerce, payments and communications. Since its inception, eBay Inc. has expanded to include some of the strongest brands in the world, including eBay, PayPal, Skype, StubHub, Shopping.com and others. eBay Inc. is headquartered in San Jose, California.
Go here to read the rest:
eBay Sellers Access 3rd-Party Applications Within My eBay
IpAuctions (R), Inc. will auction three medical patents on behalf of the Technology Licensing Office at the University of Arkansas for Medical Sciences (UAMS).
The first patent (U.S. Patent #7,074,568) would enable the commercialization of a diagnostic test kit capable to detect Mycobacterium Other Than Tuberculosis (MOTT) and would produce a rapid diagnoses of infections in humans or animals.
Mycobacteria are persistent infections organisms that are involved in several of infectious diseases in addition to those involved in Tuberculosis. The rapid identification of mycobacteria is important to control these infections and their medical management. Arkansas investigators have developed a novel procedure that is PCR-based and is effective to diagnose Mycobacteria Other Than Tuberculosis (MOTT) infections directly from patient specimens in clinical testing. This method is far superior to classical testing methods and biochemical tests.
The second patent (U.S. Patent #6,993,377) discloses rapid multi-parametric methods of diagnosing heart disease. Specifically, this invention will predict impending sudden death, and analyze patients’ responses to treatments.
Roughly 12 million Americans are affected by coronary artery disease (CAD). In addition, 400,000 Americans die from sudden cardiac death each year. To date, no conventional diagnostic test can reliably predict which patients with cardiovascular disease are at risk for sudden death. The Struzik method of multifractal analysis was successful - yet, to date, no conventional diagnostic test (including highly invasive tests) can reliably predict which patients with cardiovascular disease are at risk for sudden death.
The salient novel features of the invention are:
1) Improved rapid method of MF Holder analysis with the associated
MFCC,
2) Rapid method of MF Alpha analysis,
3) Method of removing abnormal/ectopic beats that reduce
sensitivity/specificity of MF analysis,
4) Method of beat cluster analysis of value in predicting the
severity of abnormal/ectopic beats, and
5) Battery of 6 different diagnostic tests that may be performed on
a single EKG time series, which may have much greater diagnostic
and predictive value than that of each test alone.
The third patent (U.S. Patent #6,423,076) is a stereo tactic device for localizing an MRI-imaged mass using horizontal and vertical protractors on which a laser is mounted. This invention provides radiologists performing biopsies and ablations a visual guide reference for insertion of medical devices into a tissue mass that has been localized by magnetic resonance imaging. The laser apparatus is designed to guide surgical procedures based on location information derived from MRI imaging. This system can be adapted to any type of patient table used for delivering a patient to the bore of a MRI magnet or other imaging device. The device is battery powered and self contained, thus independent of any power requirements of the MRI system. After inputting angle measurements into the stereo tactic device, the radiologists are able to follow the laser beam with a biopsy needle to make consistent arrival at the mass site. Additionally, multiple pathways can be targeted from the same entry site or multiple approaches to the target.
About University of Arkansas for Medical Sciences (UAMS) - UAMS is Arkansas’ only comprehensive academic health center, with five colleges, a graduate school, a new 540,000-square-foot hospital, six centers of excellence and a statewide network of regional centers. UAMS has 2,652 students and 733 medical residents. Its centers of excellence include the Rockefeller Cancer Institute, Stephens Spine & Neurosciences Institute, the Myeloma Institute for Research and Therapy, Jones Eye Institute, the Psychiatric Research Institute and the Reynolds Institute on Aging. Visit www.uams.edu/bioventures).
About IpAuctions(R), Inc. (www.IpAuctions.com) is the leading online auction firm specializing in the sale of intellectual property assets. The firm has a proprietary database of thousands of IP attorneys, corporate and private buyers, and venture capitalists. IpAuctions Inc. is a member of the National Auctioneers Association and the ABI. The company is based in Reno, Nevada.
Go here to read the rest:
IpAuctions, Inc. to Sell Medical Patents on Behalf of UAMS BioVenture
Vauxhall Motors’ parent company, General Motors of America, is to sell its new cars on eBay. The motor manufacturer has struck a deal with the online auction giant to pilot a scheme in California to test the water to see if this is a viable scheme to compensate for its falling sales. Some 225 of the 250 dealers General Motors has in California have signed up to the deal.
GM’s marques include Buick, Chevrolet, GMC and Pontiac, and more than 20,000 new vehicles will initially be listed on the joint website gm.ebay.com. The pilot scheme will last until the 8th September, at which time GM will assess the success of the venture and decide if it is worthwhile to expand the activity. eBay already has an existing arrangement with GM, which was initiated in February 2008, to sell its certified used cars on the auction website.
The website allows customers to compare pricing across models and participating dealerships, negotiate prices and arrange finance and payment. As with other eBay items customers can pay the “Buy it Now” price or make an offer and haggle.
See the original post here:
eBay to Auction New Cars for General Motors
IpAuctions, Inc. (www.ipauctions.com) will auction six pharmaceutical patent applications on behalf of pharmaceutical technology company Accu-Break Pharmaceuticals, Inc. (ABP) (www.accubreak.com) of Plantation, Florida, United States.
The first of the available applications, entitled “Method of Treating Hypertension With A Very Low Dose of Chlorthalidone,” has a number of claims already allowed. Allowance of additional pending claims appears to be available by making minor amendments, such as changing the claim dependency. NIH-sponsored studies have indicated that chlorthalidone (CTD) is safer and more effective than hydrochlorothiazide (HCTZ) and as a result, CTD became the diuretic of choice for a number of major NIH outcomes studies, including ALLHAT. CTD is approximately twice as potent as HCTZ and provides several day control of blood pressure compared to HCTZ, which is barely a once-a-day product. An opportunity to potentially provide a 6.25mg dose of CTD (especially in combination with a second antihypersensitive agent) would yield a product with an improved side-effect profile and efficacy. There are no low-dose CTD products on the market today, despite its proven safety and efficacy.
The second application is directed to “Methods of Treating Dialysis-Induced Hypotension,” and claims a novel treatment using an antihypotensive, e.g., midodrine, desglymidodrine, or the like. There is a present need for an effective treatment of intra-dialytic hypotension (IDH) that occurs in patients undergoing dialysis for acute renal failure. There is also a need for symptomatic treatment, in addition to the prophylactic use, of an antihypotensive agent to increase systolic blood pressure in a patient while undergoing dialysis. This application discloses novel methods of treating and preventing the serious and unpleasant syndrome of IDH in dialysis patients while undergoing treatment, including treatment for acute renal failure.
The third application is for “Compositions and Methods Using a Cardiac Glycoside.” This application claims methods and dosage forms using a low dose of digoxin or digitoxin in patients suffering from reduced creatinine clearance, renal insufficiency or chronic renal failure, and concomitant cardiovascular disease. The application is currently under a restriction requirement for election of the methods or dosage forms as described and claimed.
The fourth application relates to “Novel Compositions and Treatment of Type II Diabetes and Hypertension” and claims methods and dosage forms using a thiazolidinedione (glitazone) in combination with a thiazide or thiazide-type diuretic (e.g., HCTZ) to prevent or treat edema induced by the glitazone. This treatment is advantageous over the recommended withdrawal of glitazone administration following development of the side effect of fluid retention, and may be an effective alternative to the use of loop diuretics.
The fifth application is for “Compositions and Methods Using Torsemide” and claims clinical utility of low-dose torsemide, and dosage forms having novel score patterns that readily provide those low doses. Also included as part of the invention are products combining torsemide with antidiabetics, such as glitazones. These novel approaches can provide the advantages of lower doses (and consequent lower side effects) while providing greater dosing flexibility during treatment, e.g., a graduated dosing regimen in pre-diabetic patients.
The sixth application relates to “Compositions and Methods Comprising a Thiazide Diuretic and a Mineralocorticoid Inhibitor.” This application claims methods and dosage forms employing low doses of an aldosterone antagonist (mineralocorticoid inhibitor), such as spironolactone or eplerenone, and a thiazide, such as chlorthalidone, for co-administration or in a combination dosage form. The lower doses of active ingredient(s) allow for reduced side effects, including lower risk of potassium loss (hypokalemia), with additive or synergistic effects for treatment or prevention of cardiovascular diseases, such as hypertension, heart failure, and related disorders.
ABP is selling the patent applications “because the focus and strategy of the Company has changed with the development of its innovative Accu-Break® tablet technologies,” explained Robert I. Goldfarb, President of ABP.
About Accu-Break Pharmaceuticals, Inc.
ABP is a private pharmaceutical technology company headquartered in South Florida. ABP is developing Accu-Break® technologies for pharmaceutical tablets. The innovative and patented technologies allow the creation of tablets that can be easily divided by hand into exact smaller doses, offering complete dose flexibility via risk free tablet splitting. The Company believes that these Accu-Break® technologies offer a differentiated and clinically beneficial advantages compared to conventional dosage forms and may be applied to single and combination drug products, standard and controlled release formulations with broad applicability in human and veterinary prescription and OTC medicines. Accu-Break technologies can provide:
Product differentiation through value added product enhancements
Life cycle management
Solutions for incompatible APIs
Easy dose adjustment for accurate and customized dosing needs
Clinical trial efficiencies through the use of multi-dose tablets
About IpAuctions®, Inc.
IpAuctions®, Inc. (www.IpAuctions.com) is the leading online auction firm specializing in the sale of intellectual property assets. The firm has a proprietary worldwide database of over 8,500 IP attorneys, corporate and private buyers, and venture capitalists who wish to monetize their intellectual property.
Read the original:
IpAuctions, Inc. to Sell Six Medical Patent Applications
